X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4986) 4986
Book Review (600) 600
Publication (292) 292
Newsletter (66) 66
Book Chapter (26) 26
Magazine Article (25) 25
Conference Proceeding (8) 8
Dissertation (5) 5
Newspaper Article (3) 3
Book / eBook (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4333) 4333
humans (2482) 2482
animals (2336) 2336
male (1744) 1744
female (1296) 1296
lactones - pharmacology (1191) 1191
pharmacology & pharmacy (1185) 1185
lactones - therapeutic use (988) 988
lactones - administration & dosage (911) 911
rats (895) 895
lactones (806) 806
mice (795) 795
lactones - adverse effects (655) 655
adult (571) 571
middle aged (543) 543
lactones - chemistry (476) 476
analysis (436) 436
dose-response relationship, drug (422) 422
research (395) 395
chemistry, medicinal (390) 390
sulfones (384) 384
aged (380) 380
sesquiterpene lactones (340) 340
biochemistry & molecular biology (334) 334
rofecoxib (326) 326
abridged index medicus (321) 321
time factors (314) 314
cancer (309) 309
treatment outcome (289) 289
oncology (284) 284
rats, sprague-dawley (278) 278
apoptosis (276) 276
celecoxib (276) 276
ivermectin (275) 275
administration, oral (274) 274
sulfones - adverse effects (262) 262
inhibition (249) 249
pharmacokinetics (249) 249
plant extracts - pharmacology (249) 249
cyclooxygenase inhibitors - adverse effects (247) 247
obesity - drug therapy (247) 247
drugs (246) 246
in-vitro (245) 245
ginkgolides (235) 235
double-blind method (233) 233
cell line, tumor (232) 232
inflammation (232) 232
parasitology (232) 232
rats, wistar (230) 230
care and treatment (229) 229
expression (229) 229
health aspects (228) 228
plant sciences (225) 225
orlistat (223) 223
sesquiterpenes - pharmacology (222) 222
lactones - pharmacokinetics (221) 221
anti-inflammatory agents, non-steroidal - adverse effects (217) 217
obesity (215) 215
nonsteroidal antiinflammatory drugs (214) 214
disease models, animal (212) 212
drug therapy (212) 212
diterpenes (209) 209
anti-obesity agents - therapeutic use (207) 207
cyclooxygenase 2 (202) 202
lactones - metabolism (202) 202
medicine, general & internal (198) 198
risk factors (196) 196
cyclooxygenase inhibitors - therapeutic use (192) 192
cells (187) 187
cyclooxygenase 2 inhibitors (185) 185
physiological aspects (185) 185
united states (185) 185
chemistry, analytical (183) 183
adolescent (180) 180
anti-inflammatory agents, non-steroidal - therapeutic use (180) 180
apoptosis - drug effects (180) 180
lactone (177) 177
toxicology (177) 177
cox-2 inhibitors (171) 171
efficacy (166) 166
veterinary sciences (165) 165
drug therapy, combination (163) 163
sulfones - therapeutic use (163) 163
membrane proteins (162) 162
chemistry, multidisciplinary (159) 159
mass spectrometry (159) 159
nf-kappa-b (159) 159
platelet activating factor - antagonists & inhibitors (158) 158
immunology (157) 157
macrolides (157) 157
metabolites (156) 156
pharmacology (156) 156
rheumatoid-arthritis (155) 155
sulfones - administration & dosage (153) 153
microbiology (151) 151
oxidative stress (145) 145
cell survival - drug effects (143) 143
cyclooxygenase inhibitors - pharmacology (143) 143
drug interactions (143) 143
macrocyclic lactones (143) 143
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4877) 4877
German (94) 94
Chinese (32) 32
French (30) 30
Japanese (18) 18
Spanish (13) 13
Italian (6) 6
Russian (6) 6
Polish (5) 5
Danish (3) 3
Dutch (3) 3
Hungarian (3) 3
Norwegian (3) 3
Swedish (3) 3
Hebrew (2) 2
Korean (2) 2
Portuguese (2) 2
Romanian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA, ISSN 0098-7484, 11/2003, Volume 290, Issue 18, pp. 2411 - 2418
Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2006, Volume 33, Issue 10, pp. 917 - 924
SUMMARY • Non-steroidal anti-inflammatory drugs (NSAIDs) cause renal side-effects. In the present study, we tested the hypothesis that the extent of the renal... 
pharmacokinetics | kidney | non-steroidal anti-inflammatory drugs | cyclo-oxygenase-2 | sodium urinary excretion | cyclo‐oxygenase‐2 | non‐steroidal anti‐inflammatory drugs | Cyclo-oxygenase-2 | Pharmacokinetics | Kidney | Non-steroidal anti-inflammatory drugs | Sodium urinary excretion | GASTROINTESTINAL TOXICITY | PHYSIOLOGY | CYCLOOXYGENASE-2 | RAT | HYPERKALEMIA | PROTEIN-BINDING | MELOXICAM | INTERSPECIES DIFFERENCES | GENTAMICIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY & PHARMACY | Thiazoles - blood | Area Under Curve | Thiazines - administration & dosage | Thiazines - adverse effects | Sulfones - adverse effects | Male | Thiazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Lactones - pharmacokinetics | Sodium - urine | Lactones - administration & dosage | Pyrazoles - blood | Pyrazoles - pharmacokinetics | Sulfones - blood | Placebos - administration & dosage | Pyrazoles - adverse effects | Thiazines - pharmacokinetics | Kidney - drug effects | Administration, Oral | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Thiazines - blood | Celecoxib | Lactones - adverse effects | Placebos - pharmacokinetics | Sulfones - pharmacokinetics | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Rats, Sprague-Dawley | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Potassium - urine | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Kidney, drug effects | Lactones, adverse effects | Sulfones, administration and dosage | Thiazoles, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Sodium, urine | Thiazines, blood | Anti-Inflammatory Agents, Non-Steroidal, blood | Lactones, administration and dosage | Cyclooxygenase 2 Inhibitors, adverse effects | Pyrazoles, blood | Sulfonamides, pharmacokinetics | Thiazines, pharmacokinetics | Pyrazoles, administration and dosage | Thiazoles, blood | Sulfonamides, administration and dosage | Cyclooxygenase 2 Inhibitors, administration and dosage | Lactones, pharmacokinetics | Sulfonamides, blood | Cyclooxygenase 2 Inhibitors, pharmacokinetics | Thiazines, adverse effects | Lactones, blood | Thiazoles, adverse effects | Thiazoles, pharmacokinetics | Sulfones, blood | Sulfonamides, adverse effects | Thiazines, administration and dosage | Placebos, pharmacokinetics | Sulfones, pharmacokinetics | Pyrazoles, adverse effects | Placebos, administration and dosage | Potassium, urine | Sulfones, adverse effects | Pyrazoles, pharmacokinetics | Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 09/2013, Volume 170, Issue 2, pp. 440 - 457
BACKGROUND AND PURPOSE Flavonols and terpene lactones are putatively responsible for the properties of Ginkgo biloba leaf extracts that relate to prevention... 
inkgo biloba | GBE50 | terpene lactones | systemic exposure | ing injection | flavonols | pharmacokinetics | cerebral exposure | markers | route of administration | Ginkgo biloba | ShuXueNing injection | PK markers | ALZHEIMERS-DISEASE | EGB 761(R) | CORONARY-ARTERY | BIOAVAILABILITY | ADHESION MOLECULE EXPRESSION | QUERCETIN | PLASMA | ENDOTHELIAL-CELLS | IN-VIVO | PHARMACOLOGY & PHARMACY | BRAIN | Plant Extracts - chemistry | Plant Leaves | Flavonols - pharmacokinetics | Biological Availability | Male | Flavonols - isolation & purification | Glycosides - administration & dosage | Brain - metabolism | Plant Extracts - administration & dosage | Tissue Distribution | Lactones - pharmacokinetics | Lactones - administration & dosage | Mass Spectrometry | Chromatography, Liquid | Flavonols - administration & dosage | Drugs, Chinese Herbal - administration & dosage | Terpenes - isolation & purification | Lactones - isolation & purification | Administration, Oral | Rats | Ginkgo biloba - chemistry | Rats, Sprague-Dawley | Drugs, Chinese Herbal - pharmacokinetics | Animals | Microdialysis | Terpenes - administration & dosage | Terpenes - pharmacokinetics | Plant Extracts - pharmacokinetics | Glycosides - pharmacokinetics | Liquid chromatography | Medicine, Herbal | Medicine, Botanic | Lactones | Rodents | Chromatography | Human exposure | Index Medicus | Research Papers
Journal Article
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 02/2014, Volume 52, Issue 1, pp. 180 - 190
Journal Article
European Journal of Pharmaceutics and Biopharmaceutics, ISSN 0939-6411, 02/2014, Volume 86, Issue 2, pp. 167 - 177
Journal Article
Pharmacology, Biochemistry and Behavior, ISSN 0091-3057, 11/2012, Volume 103, Issue 1, pp. 43 - 52
There is an evolving consensus that mild cognitive impairment (MCI) serves as a prodrome to Alzheimer's disease. Antioxidants and COX-2 (cyclo-oxygenase-2)... 
Montelukast | Neuroinflammation | Rofecoxib | Mild cognitive impairment | Kainic acid | KINASE PATHWAY | CYSTEINYL LEUKOTRIENE RECEPTOR-1 | BRAIN-INJURY | ALZHEIMERS-DISEASE | FOCAL CEREBRAL-ISCHEMIA | BLOCKER MONTELUKAST | REPERFUSION INJURY | CORTICAL CONTUSION | NEUROSCIENCES | FACTOR-ALPHA LEVEL | BEHAVIORAL SCIENCES | PHARMACOLOGY & PHARMACY | MICE | Memory - drug effects | Tumor Necrosis Factor-alpha - metabolism | Rats, Wistar | Glutathione - metabolism | Cognition Disorders - chemically induced | Motor Activity - drug effects | Hippocampus - drug effects | Quinolines - administration & dosage | Lactones - administration & dosage | Leukotriene Antagonists - administration & dosage | Kainic Acid - toxicity | Neuroprotective Agents - administration & dosage | Caffeic Acids - administration & dosage | Oxidation-Reduction | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Neurotoxins - toxicity | Hippocampus - pathology | Cognition Disorders - drug therapy | Maze Learning - drug effects | Lipoxygenase Inhibitors - administration & dosage | Drug Synergism | Hippocampus - metabolism | Animals | Acetates - administration & dosage | Antioxidants - administration & dosage | Oxidative Stress - drug effects | Acetylcholinesterase - metabolism | Sulfones - administration & dosage | Antioxidants | COX-2 inhibitors | Cognition disorders | Index Medicus
Journal Article
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, ISSN 1941-7705, 05/2009, Volume 2, Issue 3, pp. 155 - 163
Background-The cardiovascular safety of individual nonsteroidal antiinflammatory drugs (NSAIDs) is highly controversial, particularly in persons with serious... 
coxib | CARDIAC & CARDIOVASCULAR SYSTEMS | celecoxib | myocardial infarction | RANDOMIZED CONTROLLED-TRIAL | CYCLOOXYGENASE | CARE | naproxen | ELDERLY PERSONS | rofecoxib | coronary disease | antiinflammatory agents, nonsteroidal | COLORECTAL-CANCER | SASKATCHEWAN | ACUTE MYOCARDIAL-INFARCTION | SUDDEN CARDIAC DEATH | INHIBITORS | diclofenac | VALIDITY | Myocardial Infarction - mortality | Follow-Up Studies | Humans | Middle Aged | Sulfones - adverse effects | Male | Incidence | Outpatients - statistics & numerical data | Cyclooxygenase 2 Inhibitors - adverse effects | Lactones - administration & dosage | Naproxen - administration & dosage | Cardiovascular Diseases - mortality | Female | Retrospective Studies | Stroke - mortality | Pyrazoles - adverse effects | Naproxen - adverse effects | Diclofenac - adverse effects | Cyclooxygenase 2 Inhibitors - administration & dosage | Risk Factors | Ibuprofen - administration & dosage | Hospitalization | Celecoxib | Coronary Artery Disease - mortality | Lactones - adverse effects | Tennessee - epidemiology | Pyrazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Sulfonamides - adverse effects | Aged | Ibuprofen - adverse effects | Diclofenac - administration & dosage | Sulfonamides - administration & dosage | Cohort Studies | Sulfones - administration & dosage | Index Medicus
Journal Article
Saudi Pharmaceutical Journal, ISSN 1319-0164, 09/2017, Volume 25, Issue 6, pp. 944 - 953
Methoxy poly(ethylene oxide)- -poly(ɛ-caprolactone) (PEO- -PCL) copolymers are amphiphilic and biodegradable copolymers designed to deliver a variety of drugs... 
Poly(ɛ-caprolactone) | Methoxy poly(ethylene oxide) | Micelles | Block copolymer | PEO-b-PCL | Poly(epsilon-caprolactone) | SOLUBILIZATION | ROUTES | DRUG-DELIVERY | SUBSTANCES | FORMULATION | EVAPORATION | CYCLOSPORINE-A | PHARMACOKINETICS | SYSTEMS | PHARMACOLOGY & PHARMACY | Drug delivery devices | Properties | Innovations | Lactones | Drugs | Pharmaceutical research | Drug delivery systems | Vehicles | Original
Journal Article
AAPS PharmSciTech, ISSN 1530-9932, 8/2017, Volume 18, Issue 6, pp. 1946 - 1959
Paliperidone (PPD) is the most recent second-generation atypical antipsychotic approved for the treatment of schizophrenia. An immediate release dose causes... 
Biochemistry, general | Biotechnology | Biomedicine | nanolipomer | Pharmacy | paliperidone | schizophrenia | ex vivo permeation | Pharmacology/Toxicology | hybrid system | CHITOSAN | NANOCAPSULES | RELEASE | FORMULATION | CARRIERS | IN-VITRO | ORAL-DRUG DELIVERY | PHARMACOLOGY & PHARMACY | OPTIMIZATION | HYBRID NANOPARTICLES | Polymers - administration & dosage | Nanoparticles - chemistry | Rats, Wistar | Intestinal Absorption - drug effects | Drug Carriers - administration & dosage | Caproates - chemistry | Paliperidone Palmitate - metabolism | Paliperidone Palmitate - administration & dosage | Drug Carriers - chemistry | Lipids - chemistry | Lactones - administration & dosage | Nanoparticles - metabolism | Female | Caproates - metabolism | Organ Culture Techniques | Intestinal Absorption - physiology | Lactones - chemistry | Drug Carriers - metabolism | Paliperidone Palmitate - chemistry | Administration, Oral | Caproates - administration & dosage | Rats | Lipids - administration & dosage | Lactones - metabolism | Antipsychotic Agents - administration & dosage | Particle Size | Animals | Antipsychotic Agents - chemistry | Antipsychotic Agents - metabolism | Polymers - chemistry | Nanoparticles - administration & dosage | Polymers - metabolism | Nanoparticles | Schizophrenia | Drugstores | Antipsychotic drugs | Permeability | Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2016, Volume 230, pp. 64 - 72
Glucocorticoid (GC) is the cornerstone therapy of rheumatoid arthritis, but high doses are associated with serious adverse effects. In an effort to improve the... 
PCL–PEG | Dexamethasone | Rheumatoid arthritis | Side effect | PCL-PEG | GLUCOCORTICOIDS | COMPLEMENT ACTIVATION | CHEMISTRY, MULTIDISCIPLINARY | STRATEGIES | PHOSPHATE | NANOPARTICLES | THERAPY | DRUGS | CONJUGATE | PHARMACOLOGY & PHARMACY | LIPOSOMES | Dexamethasone - chemistry | Tumor Necrosis Factor-alpha - metabolism | Arthritis, Experimental - drug therapy | Rats, Wistar | Humans | Polyethylene Glycols - chemistry | Polyethylene Glycols - therapeutic use | Arthritis, Experimental - metabolism | Drug Delivery Systems | Arthritis, Experimental - pathology | Arthritis, Rheumatoid - metabolism | Lactones - pharmacokinetics | Arthritis, Rheumatoid - drug therapy | Interleukin-1beta - metabolism | Lactones - administration & dosage | Micelles | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Complement C3a - metabolism | Joints - metabolism | Lactones - chemistry | Cell Survival - drug effects | Dexamethasone - administration & dosage | Human Umbilical Vein Endothelial Cells - drug effects | Cells, Cultured | Coumarins - administration & dosage | Polyethylene Glycols - pharmacokinetics | Joints - pathology | Lactones - therapeutic use | Polyethylene Glycols - administration & dosage | Arthritis, Rheumatoid - pathology | Dexamethasone - pharmacokinetics | Dexamethasone - therapeutic use | Macrophages - metabolism | Animals | Anti-Inflammatory Agents - chemistry | Hindlimb - pathology | Drug Liberation | RAW 264.7 Cells | Mice | Rheumatoid factor | Ethylene glycol | Analysis | Dosage and administration | Arthritis | Drug therapy | Steroids | Drugs | Drug delivery systems | Blood sugar | Drugstores | Vehicles | Pharmacy | Central nervous system depressants | Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2016, Volume 233, pp. 29 - 38
Journal Article